Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study

Netakimab (NTK) is a humanized anti-interleukin-17А (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Here, we present the results of the 24-weeks double blind period of the PATERA study.

Objective. The objective of the study was to evaluate the efficacy and safety of NTK compared to placebo in patients with psoriatic arthritis (PsA).

Patients and methods. 194 patients with active PsA with an inadequate response to previous therapy with nonsteroidal anti-inflammatory drugs, conventional or biologic disease-modifying antirheumatic drugs, were randomized in a 1:1 ratio to receive subcutaneous 120 mg NTK or placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22. At week 16 ACR20 (20% improvement in the American College of Rheumatology response criteria) non-responders in placebo group were reassigned to NTK in a blinded manner. The primary endpoint was the proportion of patients achieved ACR20 response at week 24.

Results. 82,5% of patients in the NTK group and 9.3% of patients in the placebo group achieved ACR20 at week 24 with the 95% CI [0,63; 0,84] (p < 0,0001). Skin manifestations and axial disease significantly improved with NTK. The safety profile of NTK was comparable to placebo. The most frequent treatment-related AEs were expected and common for all other IL-17 inhibitors: increased alanine aminotransferase (ALT), infections, lymphopenia.

Conclusion. NTK in the dose of 120 mg has superior efficacy over placebo in patients with active psoriatic arthritis. The safety profile is consistent with other IL-17 inhibitors.

1. Gladman D.D. Axial disease in psoriatic arthritis. Curr Rheumatol Rep. 2007;9(6):455–460. DOI: 10.1007/s11926-0070074-2

2. Singh J.A., Guyatt G., Ogdie A., et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5–32. DOI: 10.1002/art.40726

3. Коротаева Т.В. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научнопрактическая ревматология. 2014;52(6):650–659. [Korotaeva T.V. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Rheumatology. Science and Practice. 2014;52(2):650–659 (In Russ.)]. DOI: 10.14412/1995-4484-2014-650-659

4. Blauvelt A., Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. DOI: 10.1007/s12016-018-8702-3

5. Kubanov A.A., Bakulev A.L., Samtsov A.V. Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD085-7/PLANETA in patients with moderate-to-severe plaque psoriasis. Vestn Dermatol Venerol. 2019;95(2):15–28 (In Russ.). DOI: 10.25208/0042-4609-2019-95-2-15-28

6. Gaydukova I., Mazurov V., Erdes S., et al. FRI0391 Netakimab improves patient-related outcomes in patients witn radiological axial spondyloarthritis: results from ramdomised phase 3 trial (ASTERA). Ann Rheum Dis. 2019;78(Suppl 2):880–881. DOI: 10.1136/annrheumdis-2019-eular.6791

7. Gaydukova I., Mazurov V., Erdes S., et al. OP0232 Netakimab reduces the disease activity of radiographic axial spondyloarthritis. Results of ASTERA study. Ann Rheum Dis. 2019;78(Suppl 2):193–194. DOI: 10.1136/annrheumdis-2019-eular.6633

8. Smirnov A., Gaydukova I., Mazurov V., et al. FRI0412 Spinal and sacroiliac joints inflammation in patients with radiographic axial spondyloarthritis treated with netakimab — 16-weeks results of multicenter, randomized, double-blind, placebo-controlled phase III ASTERA study. Ann Rheum Dis. 2019;78(Suppl 2):893–894. DOI: 10.1136/annrheumdis-2019-eular.7123

9. Taylor W., Gladman D., Helliwell P., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–2673. DOI: 10.1002/art.21972

10. Nash P., Kirkham B., Okada M., et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–2327. DOI: 10.1016/S0140-6736(17)31429-0

11. McInnes I.B., Mease P.J., Kirkham B., et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146. DOI: 10.1016/S0140-6736(15)61134-5

12. Mease P., van der Heijde D., Landewé R., et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890–897. DOI: 10.1136/annrheumdis-2017-212687

13. Mease P.J., Kavanaugh A., Reimold A., et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018;4:e000723. DOI: 10.1136/rmdopen-2018-000723

14. Mease P.J., van der Heijde D., Ritchlin C.T., et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87. DOI: 10.1136/annrheumdis-2016-209709

15. Mease P.J., Palmer J.B., Liu M., et al. Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona psoriatic arthritis/spondyloarthritis registry. J Rheumatol. 2018;45(10):1389–1396. DOI: 10.3899/jrheum.171094

16. Gossec L., Baraliakos X., Kerschbaumer A., et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. DOI: 10.1136/annrheumdis-2020-217159

17. Strober B., Leonardi C., Papp K.A., et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432–440.e417. DOI: 10.1016/j.jaad.2016.09.026

18. WHO | Tuberculosis country profiles. In WHO. World Health Organization 2020. https://www.who.int/tb/country/data/profiles/en/